Review

DOI: 10.5582/irdr.2025.01051

Mitochondrial DNA A3243G variant: Current perspectives and clinical implications

Kuan-Yu Chu[1,2,*]

[1] School of Dentistry and Graduated Institute of Dental Science, College of Oral Medicine, National Defense Medical University, Taipei, Taiwan;
[2] Interdisciplinary Education Center, MacKay Junior College of Medicine, Nursing and Management, Taipei, Taiwan.

SUMMARY: The mitochondrial DNA A3243G variant, located in the MT-TL1 gene encoding $tRNA^{Leu(UUR)}$, represents one of the most clinically significant pathogenic mitochondrial mutations. This point mutation accounts for approximately 80% of Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS) syndrome cases and is the primary cause of Maternally Inherited Diabetes and Deafness (MIDD) syndrome. The clinical spectrum associated with this mutation ranges from asymptomatic carriers to severe multisystem disease with early mortality. The pathophysiology involves impaired mitochondrial protein synthesis leading to respiratory chain dysfunction, with phenotypic expression determined by heteroplasmy levels and tissue-specific energy demands. Understanding the complex inheritance patterns, genetic bottleneck effects during oogenesis, and heteroplasmy variations is crucial for comprehending the variable clinical presentations observed in affected families. Histological examination reveals characteristic features including ragged-red fibers, cytochrome c oxidase-deficient fibers, and abnormal mitochondrial proliferation. Current therapeutic approaches focus on metabolic support, antioxidant therapy, and management of specific complications, with L-arginine showing promise for stroke-like episodes. However, careful attention to drug safety profiles and potential mitochondrial toxicity is essential in treatment planning. Understanding the diverse clinical manifestations and implementing appropriate screening strategies are crucial for early diagnosis and optimal patient management. This review synthesizes current knowledge regarding the A3243G variant's pathophysiology, clinical features, diagnostic approaches, and therapeutic interventions.

Keywords: MELAS syndrome, point mutation, lactic acidosis, mitochondrial DNA (mtDNA), transfer RNA ($tRNA^{Leu(UUR)}$), heteroplasmy

1. Introduction

Mitochondrial DNA disorders encompass a heterogeneous group of inherited diseases that impair oxidative phosphorylation (OXPHOS) (*1*). Among more than 400 reported mtDNA variants, the A3243G transition in MT-TL1 is both prevalent and clinically important, with a population frequency estimated at 7.6–236 per 100,000 (*2,3*). Initially linked to Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS), A3243G is now recognized as the genetic basis for a wide array of phenotypes (*1*). The mutation disrupts $tRNA^{Leu(UUR)}$ structure, diminishing aminoacylation and mitochondrial protein synthesis (*4*), and is classically associated with MELAS and Maternally Inherited Diabetes and Deafness (MIDD) (*5*).

Phenotypic variability reflects heteroplasmy, tissue energy requirements, and nuclear background (*6*). Advances in molecular diagnostics, neuroimaging, and targeted therapy have improved detection and management of A3243G-related disease.

This comprehensive review examines the current understanding of the A3243G mitochondrial variant, focusing on its pathophysiology, clinical manifestations, diagnostic approaches, and therapeutic strategies, with particular emphasis on the two major associated syndromes: MELAS and MIDD.

2. Pathophysiology

2.1. Molecular mechanisms

The primary consequence of the A3243G mutation is impaired mitochondrial protein synthesis, particularly affecting the translation of mitochondrial-encoded respiratory chain subunits (*7*). The A3243G mutation occurs in the D-loop region of the *MT-TL1* gene encoding $tRNA^{Leu(UUR)}$, specifically disrupting the structure and

function of this crucial transfer RNA molecule. This mutation leads to the loss of post-transcriptional taurine modifications at the wobble uridine base (τm5U; 5-taurinomethyluridine), which are essential for accurate codon recognition and efficient translation (*8*).

The absence of τm5U modifications specifically impairs the recognition of UUG leucine codons while having minimal effect on UUA codon translation (*8*). This defect has profound implications for mitochondrial protein synthesis because the thirteen mitochondrial-encoded proteins contain varying numbers of UUG codons.

The ND6 subunit of Complex I contains the highest frequency of UUG codons among all mitochondrially-encoded proteins, making it particularly vulnerable to translational defects caused by the A3243G mutation (*9*). This explains why Complex I deficiency is the most consistent and severe biochemical abnormality observed in patients with this mutation.

The impaired UUG codon recognition leads to amino acid misincorporation during protein synthesis, resulting in the production of unstable, incorrectly folded respiratory chain subunits. These defective proteins cannot properly assemble into functional respiratory complexes and are rapidly degraded by mitochondrial quality control mechanisms (*10*). This results in deficiencies of complexes I, III, and IV of the electron transport chain, with complex I showing the most consistent and severe impairment (*11*). The A3243G mutation demonstrates dominant negative effects, where mutant tRNAs interfere with the normal processing of wild-type mitochondrial transcripts (*12*).

2.2. Bioenergetic consequences

The respiratory chain deficiency associated with the A3243G mutation leads to multiple bioenergetic abnormalities. Affected cells demonstrate reduced ATP synthesis, increased lactate production, and compromised maximal oxygen uptake capacity (*6*). Studies using induced neurons derived from A3243G patients have revealed heteroplasmy-dependent decreases in basal respiration, ATP-linked respiration, and spare respiratory capacity (*13*).

The mutation also triggers excessive reactive oxygen species (ROS) production, particularly in cells with high heteroplasmy levels. This oxidative stress contributes to mitochondrial membrane potential dissipation and promotes mitochondrial fragmentation through altered dynamics favoring fission over fusion (*13*). The combination of impaired ATP production and increased oxidative stress creates a cellular environment conducive to dysfunction and death, particularly in metabolically active tissues.

2.3. Tissue-specific vulnerability

Different tissues exhibit varying thresholds for mitochondrial dysfunction, correlating with their specific energy demands and reliance on oxidative phosphorylation (*14*). Tissues with high metabolic activity, such as skeletal muscle, cardiac muscle, and the central nervous system, are particularly susceptible to the effects of the A3243G mutation. The threshold effect of heteroplasmy levels determines the severity of clinical manifestations in each tissue type (*15*).

2.4. Factors contributing to phenotypic variability

The remarkable phenotypic variability observed in patients with the A3243G mutation results from multiple interconnected factors. Heteroplasmy levels represent the primary determinant of disease severity, with different tissues requiring varying thresholds of mutant mtDNA to manifest dysfunction. Skeletal muscle typically requires a 50–65% mutation load to develop symptoms, while cardiac and central nervous system manifestations may require higher thresholds of 60–90% (*16,17*).

Nuclear genetic background also significantly influences phenotypic expression. Polymorphisms in nuclear genes involved in mitochondrial biogenesis, DNA repair, and antioxidant defense can modify disease severity and age of onset. Additionally, environmental factors such as oxidative stress, infections, and metabolic demands can trigger clinical decompensation in previously asymptomatic carriers (*18*).

The tissue-specific energy demands and reliance on oxidative phosphorylation further explain the selective vulnerability observed in different organ systems. Post-mitotic tissues with high energy requirements, such as neurons, cardiac myocytes, and skeletal muscle fibers, are particularly susceptible to mitochondrial dysfunction compared to rapidly dividing tissues that can rely more heavily on glycolytic metabolism (*19*).

3. Genetic inheritance and transmission patterns

3.1. Maternal inheritance patterns

Unlike nuclear DNA disorders that follow Mendelian inheritance patterns, mitochondrial DNA mutations such as A3243G are exclusively maternally inherited. This unique inheritance pattern occurs because mitochondria are predominantly derived from the oocyte, with paternal mitochondria being actively eliminated during early embryogenesis (*20*). Consequently, all offspring of an affected mother are at risk of inheriting the mutation, while affected fathers cannot transmit the mutation to their children.

The maternal inheritance pattern has important implications for genetic counseling and family planning. Risk assessment must consider not only the presence of the mutation in the mother but also her heteroplasmy level and the potential for heteroplasmy shifts during transmission. The lack of Mendelian segregation patterns

can make genetic counseling challenging, as traditional risk calculations do not apply (*21*).

3.2. Heteroplasmy and its clinical implications

Heteroplasmy refers to the coexistence of both wild-type and mutant mitochondrial DNA within the same cell or tissue. The proportion of mutant mtDNA (mutation load) is the primary determinant of clinical phenotype severity. Importantly, heteroplasmy levels can vary significantly between different tissues within the same individual, explaining the variable organ involvement observed in A3243G patients (*22*).

Heteroplasmy levels also change over time, with most studies documenting a decline in blood mutation load with advancing age. This age-related decline in blood heteroplasmy can complicate diagnosis in older patients and may necessitate testing alternative tissues such as urine sediment or muscle biopsy for accurate genetic confirmation (*23*).

3.3. Mitochondrial genetic bottleneck

The mitochondrial genetic bottleneck represents a crucial mechanism that occurs during oogenesis and determines the heteroplasmy levels transmitted to offspring. During oocyte maturation, the mitochondrial population undergoes a significant reduction in number followed by subsequent amplification, creating an opportunity for stochastic changes in mutation load (*24*).

This bottleneck effect explains why a heteroplasmic mother can produce offspring with widely varying heteroplasmy levels, ranging from very low to very high mutation loads. The bottleneck occurs primarily during postnatal folliculogenesis rather than embryonic oogenesis, and involves replication of a small subpopulation of mitochondrial genomes (*25*). Understanding this mechanism is essential for accurate genetic counseling and risk assessment in families affected by mitochondrial disease.

4. Histological features

4.1. Skeletal muscle pathology

Skeletal muscle biopsy remains the gold standard for diagnosing mitochondrial myopathies (*26*). Characteristic histological findings include ragged-red fibers on modified Gomori trichrome staining, representing abnormal accumulations of mitochondria beneath the sarcolemma and between myofibrils. These fibers typically comprise 2-5% of total muscle fibers in A3243G patients (*27*).

Cytochrome c oxidase (COX) histochemistry reveals COX-deficient fibers, appearing as pale or negative-staining myofibers when compared with normal brown-staining fibers. Serial staining with succinate dehydrogenase (SDH) demonstrates preserved or enhanced activity in COX-deficient fibers, creating the characteristic dual-staining pattern that helps differentiate mitochondrial from other myopathies. Notably, the A3243G mutation may preserve COX staining better than other mitochondrial mutations, making SDH staining of blood vessel walls a valuable diagnostic clue (*26*).

Electron microscopy reveals ultrastructural mitochondrial abnormalities including proliferation, pleomorphism, and the presence of paracrystalline inclusions within damaged mitochondria. These changes are observed not only in skeletal muscle fibers but also in smooth muscle cells of arterioles and pericytes of capillaries, reflecting the systemic nature of mitochondrial dysfunction (*28*).

4.2. Vascular pathology

Vascular involvement represents a critical component of A3243G-associated pathology, particularly in MELAS syndrome. Histological examination reveals mitochondrial proliferation in smooth muscle cells of arterioles and capillary pericytes. These vascular changes contribute to the characteristic stroke-like episodes observed in MELAS patients and may explain the predilection for posterior cerebral involvement (*29,30*).

4.3. Central nervous system pathology

Neuropathological findings in A3243G-associated disorders include stroke-like lesions that predominantly affect the posterior cerebral regions, particularly the parietal and occipital cortices (*31*). These lesions cross vascular territories and show characteristics of cellular rather than vascular dysfunction, distinguishing them from typical ischemic strokes (*32*). Additional findings include cerebellar and cerebral atrophy, which typically occur only in severe disease and represent irreversible tissue damage (*33*).

5. Clinical features

5.1. MELAS syndrome

MELAS syndrome represents the most severe phenotypic expression of the A3243G mutation. The cardinal features include mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, though the clinical presentation is highly variable (*9*).

Stroke-like episodes occur in 95% of MELAS patients and typically manifest before age 40 years. These episodes are characterized by acute onset of focal neurological deficits, including hemiparesis, hemianopia, cortical blindness, and aphasia. Unlike typical strokes, these lesions do not follow vascular territories and may be reversible with appropriate treatment (*1*).

Seizures affect 88% of MELAS patients and may be the presenting symptom in some cases. The seizures can be focal or generalized and are often difficult to control with standard antiepileptic medications (*34*).

Encephalopathy, characterized by cognitive impairment, dementia, and psychiatric symptoms, develops in 90% of MELAS patients. This may include progressive intellectual decline, memory impairment, behavioral changes, and psychosis (*1*). Lactic acidosis, while present in 85% of cases, may be intermittent and is often most pronounced during acute episodes (*35*).

5.2. MIDD syndrome

Maternally inherited diabetes and deafness syndrome presents with a more restricted but characteristic clinical phenotype. The two cardinal features are diabetes mellitus and sensorineural hearing loss, though additional manifestations may develop over time (*36*).

Diabetes mellitus affects 90% of MIDD patients and typically presents as insulin-requiring diabetes with onset in adulthood. The diabetes is characterized by progressive β-cell dysfunction and may initially be misclassified as type 2 diabetes mellitus before the underlying mitochondrial etiology is recognized (*37*).

Sensorineural hearing loss occurs in 95% of MIDD patients and is typically progressive, bilateral, and more severe in higher frequencies (*38,39*). The hearing loss often predates the diagnosis of diabetes and may be more pronounced in males (*37*). Unlike MELAS, stroke-like episodes do not occur in MIDD syndrome, although other neurological manifestations may develop over time (*40*).

5.3. Systemic manifestations

Beyond the cardinal features of MELAS and MIDD syndromes, the A3243G mutation is associated with numerous systemic complications that may affect multiple organ systems.

Cardiac involvement manifests as cardiomyopathy in 25–30% of patients, typically presenting as hypertrophic or dilated cardiomyopathy. Conduction abnormalities are frequent and include various degrees of atrioventricular block, bundle branch blocks, and pre-excitation syndromes (*41*). Wolff-Parkinson-White syndrome has been specifically associated with MELAS patients carrying the A3243G mutation. These conduction disturbances may be progressive and can lead to sudden cardiac death if not appropriately managed (*42*).

Ocular manifestations are common and may be among the earliest signs of disease. Retinal dystrophy affects 45–75% of patients and represents the most common ocular manifestation of the A3243G mutation. The retinopathy typically presents as bilateral macular dystrophy with various degrees of retinal pigment epithelium atrophy and hyperpigmentation. Pattern dystrophy and perifoveal atrophy are characteristic findings that may precede systemic symptoms (*43*).

Table 1. Clinical Manifestations Associated with A3243G Mutation

Clinical Features	MELAS (%)	MIDD (%)	*Ref.*
Stroke-like episodes	95	0	(*1*)
Seizures	88	15	(*1,34*)
Encephalopathy	90	10	(*1*)
Lactic acidosis	85	30	(*1,35*)
Sensorineural hearing loss	75	95	(*37,39*)
Diabetes mellitus	35	90	(*36,37*)
Short stature	60	35	(*1,37*)
Exercise intolerance	80	45	(*1,39*)
Muscle weakness	75	30	(*1,6*)
Cardiomyopathy	30	25	(*14,42*)
Retinal dystrophy	45	75	(*5,43*)
Nephropathy	25	35	(*14,44*)

Renal involvement develops in 25–35% of A3243G carriers and may manifest as focal segmental glomerulosclerosis (FSGS), tubulointerstitial nephritis, or bilateral enlarged cystic kidneys (*44*). Renal involvement is often progressive and may lead to end-stage renal disease, particularly in patients with prominent systemic manifestations (*14*).

Gastrointestinal symptoms include chronic constipation, gastroparesis, and pseudo-obstruction. These manifestations likely result from mitochondrial dysfunction in smooth muscle cells of the gastrointestinal tract and may significantly impact quality of life (*45,46*).

Table 1 provides a comprehensive comparison of the clinical features observed in both syndromes, highlighting the distinct phenotypic patterns associated with each presentation.

6. Diagnostic approaches

6.1. Genetic testing

Molecular genetic testing for the A3243G mutation can be performed on various tissue types, with each offering distinct advantages and limitations. The choice of tissue depends on the clinical presentation, accessibility, and required sensitivity.

Skeletal muscle biopsy remains the gold standard for diagnosis, particularly in patients with prominent myopathic features. Muscle tissue typically harbors the highest heteroplasmy levels and provides the most reliable genetic confirmation. However, the invasive nature of muscle biopsy limits its use in some clinical scenarios.

Blood testing offers a non-invasive alternative but has limitations due to age-related decline in heteroplasmy levels. The mutation load in blood decreases with age, potentially leading to false-negative results in older patients (*47*).

Urine sediment analysis has emerged as a valuable

Table 2. Tissue-Specific Heteroplasmy Thresholds for A3243G Mutation

Tissue/Organ System	Threshold for Symptoms (%)	Diagnostic Utility	*Ref.*
Skeletal muscle	50–65	Gold standard	(*6*)
Blood	15–30	Age-dependent decline	(*45*)
Urine sediment	30–50	Stable, high sensitivity	(*43*)
Hair follicles	25–40	Accessible, moderate load	(*43*)
Buccal mucosa	20–35	Non-invasive option	(*15*)
Cardiac muscle	60–80	Functional correlation	(*42*)
Retina	45–70	Phenotype correlation	(*5,43*)
Kidney	55–75	Progressive involvement	(*14,44*)
Central nervous system	70–90	Severe manifestations	(*1*)

alternative, offering stable heteroplasmy levels that do not decline with age. This approach provides high sensitivity and specificity while remaining non-invasive (*43*).

6.2. Biochemical testing

Lactate elevation, both at rest and after exercise, represents a common biochemical abnormality in A3243G patients. However, lactate levels may be normal between acute episodes, limiting the diagnostic utility of single measurements. The lactate-to-pyruvate ratio may be more informative than absolute lactate levels.

Amino acid analysis may reveal elevated alanine levels, reflecting impaired pyruvate metabolism secondary to respiratory chain dysfunction.

6.3. Histological examination

Muscle biopsy with appropriate histological and histochemical studies remains crucial for diagnosis and phenotypic characterization. The combination of ragged-red fibers, COX-deficient fibers, and SDH enhancement provides strong supportive evidence for mitochondrial disease.

Electron microscopy, while not routinely necessary, can provide additional ultrastructural evidence of mitochondrial abnormalities and help exclude other myopathic conditions.

Table 2 summarizes the heteroplasmy thresholds and diagnostic utility of various tissue types for detecting the A3243G variant.

7. Therapeutic approaches

7.1. Metabolic support therapy

Current therapeutic strategies for A3243G-associated disorders focus primarily on metabolic support and symptom management, as no curative treatments are currently available.

Coenzyme Q10 (CoQ10) supplementation at doses of 3.4–10 mg/kg/day aims to enhance electron transport chain function and reduce oxidative stress (*48*). Clinical studies have demonstrated variable responses to CoQ10 therapy, with some patients showing improvement in exercise tolerance, reduction in lactic acidosis, and decreased frequency of stroke-like episodes (*49*). However, larger controlled studies have failed to demonstrate consistent beneficial effects across all patients, suggesting that individual responses may depend on specific genetic and phenotypic factors (*50*).

Idebenone, a synthetic CoQ10 analog, has been used at doses of 5–20 mg/kg/day and may offer advantages over CoQ10 due to its improved bioavailability and enhanced antioxidant properties (*51*).

Dichloroacetate (DCA) at doses of 25–50 mg/kg/day has been employed to reduce lactate levels by activating pyruvate dehydrogenase, though its long-term efficacy and safety profile require further evaluation (*52*).

B-vitamin supplementation, including riboflavin (50–200 mg/day), thiamine (100–300 mg/day), and nicotinamide (50–500 mg/day), is commonly used to support respiratory chain function, though evidence for clinical benefit remains limited (*53*).

7.2. L-arginine therapy

L-arginine supplementation represents one of the most promising therapeutic interventions for A3243G-associated disorders, particularly for the prevention and treatment of stroke-like episodes in MELAS syndrome.

Oral L-arginine at doses of 150-300 mg/kg/day may help prevent stroke-like episodes by improving endothelial function and nitric oxide availability (*7*).

Intravenous L-arginine at doses of 500 mg/kg during acute stroke-like episodes has shown promise in reducing the severity and duration of symptoms, though larger controlled trials are needed to establish definitive efficacy (*54*).

7.3. Supportive care and symptomatic management

Comprehensive management of A3243G-associated disorders requires a multidisciplinary approach addressing diverse systemic complications.

Cardiac monitoring and management are essential given the high frequency of cardiomyopathy and conduction abnormalities. Regular echocardiography and electrocardiographic monitoring should be performed, with prompt intervention for significant arrhythmias or heart failure (*41*).

Hearing assessment and management should include regular audiometric testing and early intervention with hearing aids or cochlear implants when appropriate (*44*).

Ophthalmologic surveillance for retinal dystrophy and other ocular complications should be performed annually (*55*).

Renal function monitoring is important given the risk

Table 3. Therapeutic Approaches for A3243G-Associated Disorders

Therapeutic Agent	Dosage	Mechanism of Action	Evidence Level	*Ref.*
L-arginine (oral)	150–300 mg/kg/day	NO precursor, endothelial function	Moderate	(*7,51*)
L-arginine (IV)	500 mg/kg during SLE	Acute SLE management	Limited	(*7,51*)
Coenzyme Q10	3.4–10 mg/kg/day	Electron transport enhancement	Moderate	(*47,49,50*)
Idebenone	5–20 mg/kg/day	Antioxidant, CoQ10 analog	Limited	(*49*)
Dichloroacetate	25–50 mg/kg/day	Lactate reduction	Limited	(*50*)
Creatine monohydrate	0.3 g/kg/day	Energy metabolism support	Limited	(*46,50*)
Riboflavin (B2)	50–200 mg/day	Respiratory chain cofactor	Limited	(*50,53*)
Thiamine (B1)	100–300 mg/day	Pyruvate metabolism	Limited	(*46,50*)
Nicotinamide (B3)	50–500 mg/day	NAD + synthesis	Limited	(*50,53*)
Supportive care	Individualized	Symptom management	Strong	(*32,46*)

of progressive nephropathy, particularly in patients with systemic manifestations (*44*).

Seizure management may require specialized expertise, as patients with mitochondrial disorders may be sensitive to certain antiepileptic drugs and may require modified treatment approaches (*50*).

7.4. Emerging therapies

Research into novel therapeutic approaches for mitochondrial diseases continues to evolve, with several promising strategies under investigation.

Gene therapy approaches are currently in various stages of development, with the most advanced applications focusing on Leber Hereditary Optic Neuropathy (LHON). Lenadogene nolparvovec has completed Phase 3 clinical trials and demonstrated efficacy and good tolerability for LHON treatment (*56*). For mtDNA disorders like those caused by A3243G mutations, gene therapy approaches face unique challenges due to the need to target mitochondria specifically.

Mitochondrial-targeted genome editing represents a breakthrough therapeutic approach. Recent developments include mitochondrial-targeted platinum transcription activator-like effector nucleases (mpTALENs) that can selectively reduce mutant mtDNA loads in patient-derived stem cells. This technology has successfully achieved mutation loads ranging from 11% to 97% in iPSCs from A3243G patients, representing a significant advance in precision mitochondrial medicine (*57*).

Mitochondrial replacement therapy and advanced gene editing approaches are in early developmental stages but face significant technical and regulatory challenges. CRISPR-based mitochondrial genome editing systems are being developed to selectively eliminate mutant mtDNA while preserving wild-type copies (*58*).

Metabolic modulators aimed at bypassing defective respiratory chain complexes or enhancing alternative energy production pathways are in various stages of preclinical and early clinical development. These include compounds targeting specific aspects of mitochondrial dysfunction beyond traditional antioxidant approaches (*59*).

7.5. Safety considerations and drug interactions

Patients with mitochondrial diseases, including those with A3243G mutations, require careful consideration of drug safety profiles due to potential mitochondrial toxicity. Several classes of medications are known to impair mitochondrial function and should be used with caution or avoided entirely in this population (*60*).

Medications to avoid or use with extreme caution include aminoglycoside antibiotics (particularly in patients with hearing loss), valproic acid (risk of severe hepatotoxicity and status epilepticus), linezolid (can cause severe lactic acidosis), and certain chemotherapeutic agents. The aminoglycoside class is particularly problematic as these antibiotics can cause irreversible hearing loss in patients with certain mtDNA mutations (*60*).

Drugs requiring careful monitoring include statins (myopathy risk), metformin (lactic acidosis risk), and certain antiepileptic drugs. When these medications are necessary, patients should be closely monitored with regular clinical assessments and laboratory studies including creatine kinase and lactate levels (*60*).

L-arginine safety profile: While generally well-tolerated, high-dose L-arginine supplementation (9–30 g/day) can cause gastrointestinal disturbances including diarrhea and nausea and may slightly reduce blood pressure. Intravenous L-arginine overdoses can lead to life-threatening hyperkalemia and hyponatremia, necessitating careful dosing and monitoring (*61*).

CoQ10 and Idebenone are generally considered safe with minimal reported adverse effects. However, therapeutic doses higher than 10 μM may be required to restore mitochondrial respiratory chain enzyme activities to control levels (*62*).

Table 3 outlines the available therapeutic agents, their mechanisms of action, and the current evidence supporting their use in patients with A3243G mutations.

8. Prognosis and disease monitoring

Prognosis for patients with A3243G-associated disorders varies significantly based on the specific clinical phenotype, age of onset, and severity of systemic

involvement. MELAS syndrome generally carries a more severe prognosis than MIDD syndrome, with increased risk of early mortality due to stroke-like episodes and multisystem complications.

Regular monitoring should include: *i*) Cardiac assessment with echocardiography and electrocardiography, *ii*) Audiometric testing for hearing loss progression, *iii*) Ophthalmologic examination for retinal complications, *iv*) Renal function assessment, *v*) Neurological evaluation for cognitive decline or new symptoms, and *vi*) Exercise tolerance and functional capacity assessment.

9. Conclusion

Current evidence establishes that the A3243G mutation affects mitochondrial protein synthesis through impaired $tRNA^{Leu(UUR)}$ function, leading to respiratory chain dysfunction that preferentially impacts metabolically active tissues. The complex interplay between heteroplasmy levels, tissue-specific energy demands, genetic bottleneck effects, and nuclear-mitochondrial interactions determines the remarkable phenotypic variability observed in affected patients. The threshold effects observed across different tissues provide important insights for both diagnostic approaches and prognostic assessment. Recognition that skeletal muscle heteroplasmy levels as low as 50% can produce symptoms challenges earlier assumptions about mutation thresholds and emphasizes importance of tissue-specific testing.

Understanding the maternal inheritance patterns, heteroplasmy dynamics, and genetic bottleneck mechanisms is essential for accurate genetic counseling and family planning. The exclusive maternal transmission and variable heteroplasmy shifts during oogenesis create unique challenges for risk assessment that differ substantially from traditional Mendelian inheritance patterns.

The multisystem nature of A3243G-associated disorders necessitates comprehensive, multidisciplinary care approaches that address not only the primary neurological and metabolic manifestations but also important systemic complications affecting cardiac, renal, retinal, and gastrointestinal systems. Early recognition and proactive management of these complications can significantly impact quality of life and long-term outcomes. Additionally, careful attention to drug safety profiles and potential mitochondrial toxicity is crucial for optimal patient management.

Recent advances in mitochondrial-targeted gene editing and cellular reprogramming technologies offer unprecedented opportunities for developing precision therapies. Successful development of tools that can modulate heteroplasmy levels in patient-derived cells represents a significant step toward therapeutic interventions that target the fundamental genetic defect.

As our understanding of mitochondrial disease mechanisms continues to evolve, the A3243G variant will undoubtedly remain a critical model for advancing both fundamental knowledge and therapeutic development in mitochondrial medicine. Lessons learned from studying this mutation have broader implications for understanding the pathophysiology of mitochondrial dysfunction and developing rational therapeutic approaches for the entire spectrum of mitochondrial diseases.

Acknowledgements

The author acknowledges the patients and families affected by mitochondrial diseases who have contributed to the research that makes reviews like this possible. I also recognize contributions of researchers worldwide who have advanced our understanding of the A3243G mutation and its clinical implications.

Funding: None.

Conflict of Interest: The author has no conflicts of interest to disclose.

References

1. Kaufmann P, Engelstad K, Wei Y, Kulikova R, Oskoui M, Battista V, Koenigsberger DY, Pascual JM, Sano M, Hirano M, DiMauro S, Shungu DC, Mao X, De Vivo DC. Protein phenotypic features of the A3243G mitochondrial DNA mutation. Arch Neurol. 2009; 66:85-91.
2. Coussa RG, Parikh S, Traboulsi EI. Mitochondrial DNA A3243G variant-associated retinopathy: Current perspectives and clinical implications. Surv Ophthalmol. 2021; 66:838-855.
3. Abad MM, Cotter PD, Fodor FH, Larson S, Ginsberg-Fellner F, Desnick RJ, Abdenur JE. Screening for the mitochondrial DNA A3243G mutation in children with insulin-dependent diabetes mellitus. Metabolism. 1997; 46:445-449.
4. Li R, Guan MX. Human mitochondrial leucyl-tRNA synthetase corrects mitochondrial dysfunctions due to the $tRNA^{Leu(UUR)}$ A3243G mutation, associated with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like symptoms and diabetes. Mol Cell Biol. 2010; 30:2147-2154.
5. Daruich A, Matet A, Borruat FX. Macular dystrophy associated with the mitochondrial DNA A3243G mutation: Pericentral pigment deposits or atrophy? Report of two cases and review of the literature. BMC Ophthalmol. 2014; 14:77.
6. Jeppesen TD, Schwartz M, Frederiksen AL, Wibrand F, Olsen DB, Vissing J. Muscle phenotype and mutation load in 51 persons with the 3243A>G mitochondrial DNA mutation. Arch Neurol. 2006; 63:1701-1706.
7. Koga Y, Povalko N, Nishioka J, Katayama K, Yatsuga S, Matsuishi T. Molecular pathology of MELAS and L-arginine effects. Biochim Biophys Acta. 2012; 1820:608-614.
8. Kamble AS, Fandilolu PM, Sambhare SB, Sonawane

KD. Idiosyncratic recognition of UUG/UUA codons by modified nucleoside 5-taurinomethyluridine, τm5U present at 'wobble' position in anticodon loop of tRNALeu: A molecular modeling approach. PLoS One. 2017; 12:e0176756.
9. Cox BC, Pearson JY, Mandrekar J, Gavrilova RH. The clinical spectrum of MELAS and associated disorders across ages: A retrospective cohort study. Front Neurol. 2023; 14:1298569.
10. Koopman WJ, Willems PH, Smeitink JA. Monogenic mitochondrial disorders. N Engl J Med. 2012; 366:1132-1141.
11. Laforêt P, Ziegler F, Sternberg D, Rouche A, Frachon P, Fardeau M, Eymard B, Lombès A. ["MELAS" (A3243G) mutation of mitochondrial DNA: A study of the relationships between the clinical phenotype in 19 patients and morphological and molecular data]. Rev Neurol (Paris). 2000; 156:1136-1147.
12. Koga Y, Povalko N, Nishioka J, Katayama K, Kakimoto N, Matsuishi T. MELAS and l-arginine therapy: Pathophysiology of stroke-like episodes. Ann N Y Acad Sci. 2010; 1201:104-110.
13. Lin DS, Huang YW, Ho CS, Huang TS, Lee TH, Wu TY, Huang ZD, Wang TJ. Impact of mitochondrial A3243G heteroplasmy on mitochondrial bioenergetics and dynamics of directly reprogrammed MELAS neurons. Cells. 2022; 12:15.
14. Guéry B, Choukroun G, Noël LH, Clavel P, Rötig A, Lebon S, Rustin P, Bellané-Chantelot C, Mougenot B, Grünfeld JP, Chauveau D. The spectrum of systemic involvement in adults presenting with renal lesion and mitochondrial *tRNA^{Leu}* gene mutation. J Am Soc Nephrol. 2003; 14:2099-2108.
15. Vuorinen AM, Lehmonen L, Auranen M, Weckström S, Kivistö S, Holmström M, Heliö, T. Cardiac involvement in patients with MELAS-Related mtDNA 3243A>G variant. Cardiogenetics. 2025; 15:16.
16. Wai T, Teoli D, Shoubridge EA. The mitochondrial DNA genetic bottleneck results from replication of a subpopulation of genomes. Nat Genet. 2008; 40:1484-1488.
17. Stewart JB, Chinnery PF. The dynamics of mitochondrial DNA heteroplasmy: Implications for human health and disease. Nat Rev Genet. 2015; 16:530-542.
18. Rossignol R, Faustin B, Rocher C, Malgat M, Mazat JP, Letellier T. Mitochondrial threshold effects. Biochem J. 2003; 370:751-762.
19. Chinnery PF, Samuels DC. Relaxed replication of mtDNA: A model with implications for the expression of disease. Am J Hum Genet. 1999; 64:1158-1165.
20. Schwartz M, Vissing J. Paternal inheritance of mitochondrial DNA. N Engl J Med. 2002; 347:576-580.
21. Poulton J, Marchington DR. Segregation of mitochondrial DNA (mtDNA) in human oocytes and in animal models of mtDNA disease: Clinical implications. Reproduction. 2002; 123:751-755.
22. Rahman S, Poulton J, Marchington D, Suomalainen A. Decrease of 3243A-->G mtDNA mutation from blood in MELAS syndrome: A longitudinal study. Am J Hum Genet. 2001; 68:238-240.
23. McDonnell MT, Schaefer AM, Blakely EL, McFarland R, Chinnery PF, Turnbull DM, Taylor RW. Noninvasive diagnosis of the 3243A>G mitochondrial DNA mutation using urinary epithelial cells. Eur J Hum Genet. 2004; 12:778-781.
24. Cree LM, Samuels DC, de Sousa Lopes SC, Rajasimha HK, Wonnapinij P, Mann JR, Dahl HH, Chinnery PF. A reduction of mitochondrial DNA molecules during embryogenesis explains the rapid segregation of genotypes. Nat Genet. 2008; 40:249-254.
25. Freyer C, Cree LM, Mourier A, Stewart JB, Koolmeister C, Milenkovic D, Wai T, Floros VI, Hagström E, Chatzidaki EE, Wiesner RJ, Samuels DC, Larsson NG, Chinnery PF. Variation in germline mtDNA heteroplasmy is determined prenatally but modified during subsequent transmission. Nat Genet. 2012; 44:1282-1285.
26. Walters J, Baborie A. Muscle biopsy: What and why and when? Pract Neurol. 2020; 20:385-395.
27. Lorenzoni PJ, Scola RH, Kay CS, Arndt RC, Freund AA, Bruck I, Santos ML, Werneck LC. MELAS: Clinical features, muscle biopsy and molecular genetics. Arq Neuropsiquiatr. 2009; 67:668-676.
28. Felczak P, Lewandowska E, Stępniak I, Ołdak M, Pollak A, Lechowicz U, Pasennik E, Stępień T, Wierzba-Bobrowicz T. Pathology of mitochondria in MELAS syndrome: An ultrastructural study. Pol J Pathol. 2017; 68:173 -181.
29. Lorenzoni PJ, Werneck LC, Kay CSK, Silvado CES, Scola RH. When should MELAS (Mitochondrial myopathy, Encephalopathy, Lactic Acidosis, and Stroke-like episodes) be the diagnosis? Arq Neuropsiquiatr. 2015; 73:959-967.
30. Kanaumi T, Hirose S, Goto Y, Naitou E, Mitsudome A. An infant with a mitochondrial A3243G mutation demonstrating the MELAS phenotype. Pediatr Neurol. 2006; 34:235-238.
31. Majamaa K, Turkka J, Kärppä M, Winqvist S, Hassinen IE. The common MELAS mutation A3243G in mitochondrial DNA among young patients with an occipital brain infarct. Neurology. 1997; 49:1331-1334.
32. Ng YS, Turnbull DM. Mitochondrial disease: Genetics and management. J Neurol. 2016; 263:179-191.
33. Sue CM, Crimmins DS, Soo YS, Pamphlett R, Presgrave CM, Kotsimbos N, Jean-Francois MJ, Byrne E, Morris JG. Neuroradiological features of six kindreds with MELAS *tRNA^{Leu}* A2343G point mutation: Implications for pathogenesis. J Neurol Neurosurg Psychiatry. 1998; 65:233-240.
34. Liu CH, Chang CH, Kuo HC, Ro LS, Liou CW, Wei YH, Huang CC. Prognosis of symptomatic patients with the A3243G mutation of mitochondrial DNA. J Formos Med Assoc. 2012; 111:489-494.
35. Zhang J, Guo J, Fang W, Jun Q, Shi K. Clinical features of MELAS and its relation with A3243G gene point mutation. Int J Clin Exp Pathol. 2015; 8:13411-13415.
36. Bukhari K, Pennant M. Mitochondrial diabetes: The clinical spectrum of MIDD and MELAS in association with the A3243G mutation. J Endocr Soc. 2021; 5:A392-A393.
37. Chanoine JP, Thompson DM, Lehman A. Diabetes associated with maternally inherited diabetes and deafness (MIDD): From pathogenic variant to phenotype. Diabetes. 2024; 74:153-163.
38. Zheng S, Wang J, Sun M, Wang P, Shi W, Zhang Z, Wang Z, Zhang H. The clinical and genetic characteristics of maternally inherited diabetes and deafness (MIDD) with mitochondrial m.3243A>G mutation: A 10-year follow-up observation study and literature review. Clin Case Rep. 2024; 12:e8458.
39. Deschauer M, Müller T, Wieser T, Schulte-Mattler W, Kornhuber M, Zierz S. Hearing impairment is common in

various phenotypes of the mitochondrial DNA A3243G mutation. Arch Neurol. 2001; 58:1885-1888.
40. Lien LM, Lee HC, Wang KL, Chiu JC, Chiu HC, Wei YH. Involvement of nervous system in maternally inherited diabetes and deafness (MIDD) with the A3243G mutation of mitochondrial DNA. Acta Neurol Scand. 2001; 103:159-165.
41. Wortmann SB, Rodenburg RJ, Backx AP, Schmitt E, Smeitink JAM, Morava E. Early cardiac involvement in children carrying the A3243G mtDNA mutation. Acta Paediatr. 2007; 96:450-451.
42. Fayssoil A. Heart diseases in mitochondrial encephalomyopathy, lactic acidosis, and stroke syndrome. Congest Heart Fail. 2009; 15:284-287.
43. Fukao T, Kondo M, Yamamoto T, Orii KE, Kondo N. Comparison of mitochondrial A3243G mutation loads in easily accessible samples from a family with maternally inherited diabetes and deafness. Mol Med Rep. 2009; 2:69-72.
44. Olsson C, Johnsen E, Nilsson M, Wilander E, Syvänen AC, Lagerström-Fermér M. The level of the mitochondrial mutation A3243G decreases upon ageing in epithelial cells from individuals with diabetes and deafness. Eur J Hum Genet. 2001; 9:917-921.
45. Alcubilla-Prats P, Solé M, Botey A, Grau JM, Garrabou G, Poch E. Kidney involvement in MELAS syndrome: Description of 2 cases. Med Clin (Barc). 2017; 148:357-361.
46. Li JY, Hsieh RH, Peng NJ, Lai PH, Lee CF, Lo YK, Wei YH. A follow-up study in a Taiwanese family with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes syndrome. J Formos Med Assoc. 2007; 106:528-536.
47. Parikh S, Saneto R, Falk MJ, Anselm I, Cohen BH, Haas R, Medicine Society TM. A modern approach to the treatment of mitochondrial disease. Curr Treat Options Neurol. 2009; 11:414-430.
48. Abe K, Matsuo Y, Kadekawa J, Inoue S, Yanagihara T. Effect of coenzyme Q10 in patients with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS): Evaluation by noninvasive tissue oximetry. J Neurol Sci. 1999; 162:65-68.
49. Hargreaves IP. Coenzyme Q10 as a therapy for mitochondrial disease. Int J Biochem Cell Biol. 2014; 49:105-111.
50. Berbel-Garcia A, Barbera-Farre JR, Etessam JP, Salio AM, Cabello A, Gutierrez-Rivas E, Campos Y. Coenzyme Q10 improves lactic acidosis, strokelike episodes, and epilepsy in a patient with MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes). Clin Neuropharmacol. 2004; 27:187-191.
51. El-Hattab AW, Adesina AM, Jones J, Scaglia F. MELAS syndrome: Clinical manifestations, pathogenesis, and treatment options. Mol Genet Metab. 2015; 116:4-12.
52. Ikawa M, Povalko N, Koga Y. Arginine therapy in mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes. Curr Opin Clin Nutr Metab Care. 2020; 23:17-22.
53. Neergheen V, Chalasani A, Wainwright L, Yubero D, Montero R, Artuch R, Iain Hargreaves. Coenzyme Q10 in the treatment of mitochondrial disease. J Inborn Errors Metab Screen. 2017; 5.
54. Ferreira F, Gonçalves Bacelar C, Lisboa-Gonçalves P, Paulo N, Quental R, Nunes AT, Silva R, Tavares I. Renal manifestations in adults with mitochondrial disease from the mtDNA m.3243A>G pathogenic variant. Nefrologia. 2023; 43:1-7.
55. Lock JH, Irani NK, Newman NJ. Neuro-ophthalmic manifestations of mitochondrial disorders and their management. Taiwan J Ophthalmol. 2021; 11:39-52.
56. Yu-Wai-Man P, Griffiths PG, Gorman GS, *et al*. Multi-system neurological disease is common in patients with OPA1 mutations. Brain. 2010; 133:771-786.
57. Yahata N, Goto YI, Hata R. Optimization of mtDNA-targeted platinum TALENs for bi-directionally modifying heteroplasmy levels in patient-derived m.3243A>G-iPSCs. Mol Ther Nucleic Acids. 2025; 36:102521.
58. Mok BY, de Moraes MH, Zeng J, Bosch DE, Kotrys AV, Raguram A, Hsu F, Radey MC, Peterson SB, Mootha VK, Mougous JD, Liu DR. A bacterial cytidine deaminase toxin enables CRISPR-free mitochondrial base editing. Nature. 2020; 583:631-637.
59. Steele H, Gomez-Duran A, Pyle A, *et al*. Metabolic effects of bezafibrate in mitochondrial disease. EMBO Mol Med. 2020; 12:e11589.
60. Haas RH, Parikh S, Falk MJ, Saneto RP, Wolf NI, Darin N, Cohen BH. Mitochondrial disease: A practical approach for primary care physicians. Pediatrics. 2007; 120:1326-1333.
61. Fiedorczuk K, Letts JA, Degliesposti G, Kaszuba K, Skehel M, Sazanov LA. Atomic structure of the entire mammalian mitochondrial complex I. Nature. 2016; 538:406-410.
62. Geromel V, Darin N, Chrétien D, Bénit P, DeLonlay P, Rötig A, Munnich A, Rustin P. Coenzyme Q10 and idebenone in the therapy of respiratory chain diseases: Rationale and comparative benefits. Mol Genet Metab. 2002; 77:21-30.

Received August 9, 2025; Revised September 17, 2025; Accepted September 25, 2025.

**Address correspondence to:*
Kuan-Yu Chu, School of Dentistry and Graduated Institute of Dental Science, College of Oral Medicine, National Defense Medical University, 114201 Neihu, Taipei, Taiwan.
E-mail: kyc0321@gmail.com

Released online in J-STAGE as advance publication October 3, 2025.